| Code | CSB-RA025833MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to CMAB801, targeting vascular endothelial growth factor A (VEGFA). VEGFA is a critical signaling protein that regulates angiogenesis and vascular permeability through binding to VEGF receptors on endothelial cells. It plays essential roles in physiological processes including wound healing and embryonic development, but aberrant VEGFA expression is implicated in numerous pathological conditions. Elevated VEGFA levels are associated with tumor angiogenesis in various cancers, diabetic retinopathy, age-related macular degeneration, and other neovascular disorders where excessive blood vessel formation contributes to disease progression.
CMAB801 is a therapeutic antibody that specifically binds and neutralizes VEGFA, preventing its interaction with cognate receptors and thereby inhibiting downstream angiogenic signaling. This biosimilar antibody provides researchers with a valuable tool for investigating VEGFA-mediated pathways, studying mechanisms of angiogenesis, and exploring anti-angiogenic therapeutic strategies in preclinical models. It is suitable for various research applications examining vascular biology, tumor microenvironment dynamics, and VEGF-dependent disease mechanisms.
There are currently no reviews for this product.